Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesPATRYS Ltd

PATRYS Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.023 AUD 0.00(0%)
Last update at 2026-11-12T05:10:00Z
VOLUME
96017
Market Cap
7.71M

Momentum Score

…

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company's portfolio includes an injectable quetiapine program for the treatment of delirium and its versatile deoxymab antibody platform, including PAT-DX1 and PAT-DX3, which is being developed for applications in inflammatory and autoimmune diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and cancers and/or metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.02
High
52 Week Price Range
0.02
Low
0.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

PATRYS Ltd (ASX: PAB) is an Australian biotechnology company focused on developing peptide-based therapeutics; public disclosures about its programs and platform are limited. Long-term growth may be driven by clinical and preclinical progress, protection of intellectual property and successful strategic collaborations, which could support translation of programs toward commercialization.

The most important investment risks are high clinical and regulatory failure risk, reliance on external funding or partners, potential dilution from future capital raises and typical execution risk for small-cap biotechs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.02
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
-
Gross Profit TTM
0.01M
Debt / Equity
-
ROE
-68.25%
Net Debt
-3.36M
ROCE
-33.64%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -3.42M -3.01M -4.82M -7.06M -6.78M
Net income -3.41M -3.01M -3.54M -7.06M -6.78M
Selling general administrative - 1.78M 1.86M 2.39M 2.03M
Gross profit - 0.83M 1.39M - 0.03M
Reconciled depreciation - 0.05M 0.05M 0.05M 0.05M
Ebit - -2.71M -3.54M -9.96M -10.13M
Ebitda -3.42M -2.66M -3.49M -9.91M -10.09M
Depreciation and amortization - 0.05M 0.05M 0.05M 0.05M
Operating income -3.42M -2.71M -3.54M -9.96M -6.78M
Other operating expenses 3.42M 3.54M 4.93M 9.96M 10.11M
Interest expense - - - - 0.01M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.02M 0.11M 0.08M 0.01M
Net interest income - 0.02M 0.11M 0.08M 0.01M
Income tax expense -0.01M -0.81M -1.29M -0.12M -0.06M
Total revenue - 0.83M 1.39M 2.85M 0.03M
Total operating expenses 3.42M 3.54M 4.93M 9.96M 10.16M
Cost of revenue - - 0.05M - -
Total other income expense net - -0.30M -1.29M 2.78M 3.30M
Net income from continuing ops - -3.01M -3.54M -7.06M -6.78M
Net income applicable to common shares - -3.01M -3.54M -7.06M -6.78M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 11.10M 1.74M 4.16M 7.52M 13.97M
Intangible assets - - 0.35M 0.39M 0.44M
Other current assets 0.06M - 0.23M - 0.29M
Total liab 0.92M 1.01M 0.69M 0.69M 0.54M
Total stockholder equity 10.18M 0.73M 3.47M 6.84M 13.43M
Other current liab 0.24M - 0.45M 0.40M 0.38M
Common stock 94.21M - 85.73M 85.73M 85.72M
Capital stock - 86.01M 85.73M 85.73M 85.72M
Retained earnings -88.88M -86.17M -83.87M -81.12M -74.30M
Other assets - - 0.00M - -
Cash 3.36M 0.74M 2.24M 3.05M 7.82M
Total current liabilities 0.92M 1.01M 0.69M 0.69M 0.54M
Net debt -3.36M - -2.24M -3.05M -7.82M
Short term debt - - - 0.00M 0.00M
Other stockholder equity 4.84M - 0.00M -4.61M -11.43M
Property plant equipment - - - 0.00M 0.00M
Total current assets 3.52M 1.74M 3.81M 7.13M 13.53M
Net tangible assets - - - 6.44M 12.99M
Short term investments - - - 1.00M 2.00M
Net receivables 0.10M - 1.34M 2.84M 3.41M
Accounts payable 0.68M 0.14M 0.24M 0.29M 0.16M
Accumulated other comprehensive income - - 1.61M 2.23M 2.00M
Non currrent assets other - - -0.00M -0.40M -0.44M
Non current assets total 7.57M 0.00M 0.35M 0.40M 0.44M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 0.00M 1.01M 1.00M 2.00M
Change to liabilities - - - 0.11M -0.14M
Total cashflows from investing activities -0.00M 0.00M 1.01M 1.00M 1.99M
Total cash from financing activities 4.79M 0.28M 0.00M 0.01M 7.56M
Change to operating activities - - - 0.08M -0.25M
Net income -3.41M -3.01M -3.54M -7.06M -6.78M
Change in cash 2.62M -1.50M -0.80M -4.77M 0.90M
Begin period cash flow 0.74M 2.24M 3.05M 7.82M 6.92M
End period cash flow 3.36M 0.74M 2.24M 3.05M 7.82M
Total cash from operating activities -2.17M -1.77M -1.82M -5.78M -8.68M
Issuance of capital stock - 0.31M 0.00M 0.01M 7.90M
Depreciation - 0.05M 0.05M 0.05M 0.05M
Other cashflows from investing activities - 0.00M 1.01M 1.00M 2.00M
Change to account receivables - 0.52M 1.50M 0.57M -2.13M
Sale purchase of stock - -0.03M 0.00M 0.01M -0.35M
Other cashflows from financing activities 0.03M - 1.01M 1.00M 1.99M
Change to netincome - - - 0.47M 0.57M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital - 0.33M 1.57M 0.57M -2.13M
Stock based compensation - - 0.16M 0.47M 0.57M
Other non cash items 1.24M 0.86M -0.06M 1.24M -1.95M
Free cash flow -2.17M -1.77M -1.82M -5.78M -8.68M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PAB
PATRYS Ltd		 -
-%		 0.02 - - 858.12 18.34 572.63 -3.85
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

PATRYS Ltd

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company's portfolio includes an injectable quetiapine program for the treatment of delirium and its versatile deoxymab antibody platform, including PAT-DX1 and PAT-DX3, which is being developed for applications in inflammatory and autoimmune diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and cancers and/or metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.

168 Stirling Highway, Nedlands, WA, Australia, 6009

61 8 6165 8858

https://patrys.com

Name Title Year Born
Dr. James A. Campbell B.Sc., MBA, Ph.D. MD, CEO & Exec. Director NA
Ms. Valentina Dubljevic BSc, GAICD, MBB VP of Scientific & Clinical Devel. NA
Dr. Deanne Greenwood B.Sc., GAICD, MBA, Ph.D. VP of Bus. Devel. & Intellectual Property NA
Dr. Rebecca Tunstall VP of Corp. Devel. NA
Mr. Stefan Ross Company Sec. NA
Dr. James A. Campbell B.Sc., MBA, Ph.D. MD, CEO & Executive Director NA
Mr. Stefan Ross Company Secretary NA
Dr. Rebecca Tunstall Vice President of Corporate Development NA
Dr. James A. Campbell B.Sc., MBA, Ph.D. MD, CEO & Executive Director NA
Mr. Stefan Ross Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…